Assertio Therapeutics (ASRT) Tops Q4 EPS by 1c ; Offers Guidance

Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $32.18 million versus the consensus estimate of $28.67 million.

GUIDANCE:

Assertio Therapeutics sees FY2025 revenue of $108-123 million, versus the consensus of $123.7 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE